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Sex-determining region Y (SRY)-box protein 2 (SOX2) plays a critical role in stem cell maintenance and
carcinogenesis. In addition to its function as a minor-groove DNA binding transcription factor, our pre-
vious study showed that SOX2 also acts as a RNA binding protein. In current study, we ﬁrst showed that
SOX2 displayed high afﬁnity toward the mRNA encoding S100A14 in BFTC905 and that depletion of SOX2
resulted in a decrease of S100A14 mRNA and protein level. To characterize the RNA binding sequence
recognized by SOX2, oligomer-directed RNase H digestion was coupled to the cross-linking before im-
munoprecipitation assay to demonstrate that SOX2 preferentially binds to the 3′-UTR of the S100A14
mRNA. Using EGFP-S100A14 3′-UTR reporters and mobility shift assay, we identiﬁed that the binding
sequence on the 3′-UTR of the S100A14 mRNA exhibits a stem-loop structure. Together, our data in-
dicates that SOX2 enhances S100A14 expression by binding to the 3′-UTR of the S100A14 mRNA.
Functionally, depletion of SOX2 increases growth and mobility of BFTC905. Knock-down of S100A14 in
BFTC905 also leads to an increase in the number of the cells in the S phase and higher mobility, sug-
gesting that SOX2 suppresses cell growth and mobility through promoting the expression of S100A14.
Together, our experimental evidence indicates that SOX2 is capable of exerting its cellular functions by
functioning as an RNA binding protein in post-transcriptional regulation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Post-transcriptional regulation mechanisms, including alter-
native splicing, mRNA stability, and translation modulation, play a
major role in creating transcriptome and proteome complexity.
Mechanistically, it is essential to select correct RNA transcripts for
regulation [1,2]. The trans-acting guide-RNA-carrying protein
complexes and RNA binding proteins are responsible to achieve
the target speciﬁcity by recognizing the cis-sequence elements on
the RNA transcripts. While the guide RNA-protein complexes,
which are typiﬁed by microRNA-loaded RNA-induced silencing
complex (RISC), achieve sequence-speciﬁc recognition through
complementary annealing of the guide RNA [3], RNA binding
proteins bind to the target RNA sequences through the RNA
binding domains [4]. It was estimated that the human genome
encodes hundreds of RNA binding proteins, but only limitedB.V. This is an open access article u
.numbers of the RNA binding protein repertoire have been ex-
tensively studied [5–7]. Given the important role of post-tran-
scriptional regulation in cellular functions, it is necessary to ad-
vance our understanding on the functions of RNA binding proteins.
RNA binding proteins binds to the target RNA transcripts
through sequence-speciﬁc RNA-binding domains [8]. Although
most of RNA binding proteins possess RNA-speciﬁc interaction
domains, such as the RNA recognition motif (RRM) and hnRNP K
homologous domain (KH domain) [8–10], some DNA binding
proteins were shown to exhibit RNA binding capabilities. One of
such versatile nucleic acid binding motifs is the zinc-ﬁnger DNA-
binding domain [11,12]. The most notable example dual function
transcription factor is Wilm’s tumor 1 (WT1), the master regulator
for the development of the urinary and reproductive systems in
mammals [13–15]. WT1 interacts with splicing factor and RNA
binding protein, including U2AF65, WTAP, and RBM4. As the result
of its RNA binding activity, WT1 performs diverse post-transcrip-
tional activities, including 3′ splice site selection in the nucleus as
well as mRNP localization and translation regulation in the cyto-
plasm [16–18]. Recently, p53, which is also a zinc-ﬁnger protein,
was implicated in microRNA biogenesis by facilitating thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[19], further supporting the zinc-ﬁnger domain can be used as
DNA binding as well as post-transcriptional RNA recognition.
Another group of the dual function transcription factors is the
members of the SOX family. The conserved nucleic acid recogni-
tion domain of the SOX proteins is the high-mobility group (HMG)
box domain [20,21]. Among the SOX proteins, SRY, SOX6, and SOX9
were shown to facilitate pre-mRNA splicing in HeLa nuclear ex-
tracts in vitro [22]. In addition, the RNA-binding domain of human
hepatitis D virus exhibits a structure similar to that of the SRY
HMG box [23]. Although these ﬁndings indicate that the HMG
domain is also used for the recognition of the RNA sequences, the
cellular functions of the SOX family of proteins in post-transcrip-
tional gene regulation have not been extensively studied.
SOX2 plays an essential role in stem cell maintenance program.
Because SOX2 exhibits DNA binding activity and acts cooperatively
with Oct4 in the stem cell maintenance pathway [24,25], it is often
assumed that SOX2 exerts its function by regulating transcription.
We previously reported that SOX2 is expressed in BFTC905 cells,
an urothelial carcinoma cell line retaining partial epithelial char-
acteristics [26]. Our data also showed that the expression of SOX2
leads to alternative splicing of the adenovirus early gene 1 A (E1A).
Recombinant SOX2 also directly binds to the E1A pre-mRNA in
vitro, indicating that SOX2 exhibits RNA-binding activity. Here, we
report that SOX2 binds to the 3′-UTR of the S100A14 mRNA and
promotes its expression. Depletion of either SOX2 or S100A14
reduced the growth and mobility of BFTC905 cells, suggesting that
SOX2 exerts its cellular function through post-transcriptionally
regulating the expression of S100A14. Thus, our study provides
experimental evidence to support the notion that the SOX proteins
are dual function proteins, acting as both transcription factors and
RNA binding proteins.2. Materials and methods
2.1. Plasmids and cell culture
BFTC905 was cultured in RPMI 1640 medium supplemented
with 1.5 g/L sodium bicarbonate and 15% fetal bovine serum
(Sigma-Aldrich, St. Louis, MO, USA), and HEK293T was cultured in
DMEM medium supplemented with 10% fetal bovine serum.
Knock-down of targeted genes was achieved by employing the
short-hairpin RNA (shRNA)-expressing lentiviral vectors obtained
from the National RNAi Core Facility (Academia Sinica, Taipei,
Taiwan). The identiﬁcation number of the anti-SOX2 shRNA clone
used in transcriptome analysis and subsequent cellular function
experiment is TRCN00000355638 with the targeted sequence 5′-
CCCTGCAGTACAACTCCATGA. An additional anti-SOX2 shRNA
clone, TRCN00000231641, was used to generate second cell line,
designated as BFTC905/shSOX2-41. The targeted sequences of
this anti-SOX2 shRNA is 5′-CAACGGCAGCTACAGCATGAT. The
identiﬁcation number of the anti-S100A14 shRNA clone is
TRCN0000056527, and the targeted sequence is 5′-CCTCATCAA-
GAACTTTCACCA. pLKO.1-shLuc, the vector expressing the anti-lu-
ciferase shRNA, served as a control. To generate the viral particles
for infection, the shRNA-expressing vectors were co-transfected
with pCMV-ΔR8.91 and pMD. G into HEK293T using Turbofect
transfection reagent (Thermo Fisher Scientiﬁc, Waltham, MA). The
packaged viruses were harvested from the culture medium and
used to infect BFTC905. Forty-eight hours after infection, BFTC905
was selected against puromycin to obtain the stable shRNA-ex-
pressing cell lines BFTC905/shLuc, BFTC905/shSOX2, BFTC905-
shSOX2–41, and BFTC905/shS100A14. BFTC905/shLuc and
BFTC905/shSOX2 were subsequently transfected with pTagRFP-N
(Evrogen, Moscow, Russia) and pEGFP-C1 (Takara, Kyoto, Japan),respectively. The ﬂuorescent protein-positive cells were selected
against 400 μg/ml G418 for two weeks and isolated using a FACS
Aria cell sorter (BD Biosciences, San Jose, CA, USA) to obtain the
BFTC905/shLuc-RFP and BFTC905/shSOX2-EGFP cells. SOX2 was
also cloned from pcDNA-SOX2 into pTagRFP-N to create pSOX2-
RFP. The pEGFP-hnRNP A1 and pEGFP-hnRNP C1 plasmids were
obtained from Dr. W. Y. Tarn (Institute of Biomedical Science,
Academia Sinica).
To create the S100A14 3′-UTR reporters, we ﬁrst obtained the
fragmented sequence of the S100A14 3′-UTR from the BFTC905
cells by reverse transcription-PCR and subsequently cloned these
fragments into pEGFP-C1 to create the EGFP-S100A14 3′-UTR
fragment reporters. These fragments correspond to the S100A14
mRNA sequence at nt 471-589, 566-622, 643-784, 758-866, 842-
930, and 907-1018. A translation stop codon was incorporated into
the 5′-end of the ampliﬁed sequences to prevent these sequences
from being translated. These reporters were transfected into
BFTC905 with either pcDNA5/TO-β-galactosidase or pcDNA5/TO-
FLAG-SOX2. The transfected cells were selected against 50 μg/ml
hygromycin for 48 h before harvest.
2.2. Cell growth determination and cell cycle analysis
To determine the growth rate, 1, 0.5, 0.25, 0.125 million
BFTC905/shLuc and BFTC905/shSOX2 cells were seeded in plates
and cultured for one, two, three, or four days, respectively. At the
end of the time period, the cells were washed with PBS, ﬁxed in 4%
paraformaldehyde, and stained with 0.01% crystal violet in water
for 30 min. The cells were then washed four times with water,
dried, and extracted with 20% acetic acid. The absorbance of the
acid extracts was measured at 595 nm. For the cell cycle analysis,
the cells were harvested and ﬁxed in 100% ethanol at 20 °C for at
least 24 h. The ﬁxed cells were treated with 5 mg/ml RNase A and
40 μg/ml propidium iodide at 37 °C for 30 min, followed by ana-
lysis by ﬂow cytometry.
2.3. Wound healing and transwell migration assays
In each chamber of the culture inserts, 20,000 control or SOX2
knocked-down cells were seeded and cultured in the medium
with 2% serum for 16 h. The inserts were then removed, and
images were taken at 0, 12, and 24 h. The transwell assay was
performed by seeding 10,000 ﬂuorescent protein-tagged cells in
the upper chamber in normal culture medium for 24 h. The
medium in the upper chamber was then replaced with the med-
ium containing 1% serum. After additional 24 h incubation, the
cells were ﬁxed in 4% paraformaldehyde for 10 min. After ﬁxation,
the total cell population was imaged using a ﬂuorescence micro-
scope with a CCD camera. The cells on the upper chamber were
then removed, and the cells in the lower chamber were imaged
using an Olympus FV1000 laser scanning microscope.
2.4. Immunoblotting
Immunoblotting was performed as described below. The pro-
tein samples were ﬁrst separated by SDS-polyacrylamide gel
electrophoresis and transferred to a Hybond-P membrane (GE
Healthcare Life Sciences, Waukesha, WI, USA). The protein-bound
membrane was blocked in 5% skim milk in phosphate-buffered
saline (PBS) containing 0.1% Tween 20, followed by hybridization
of the primary antibodies overnight at 4 °C. The secondary anti-
bodies used for detection were horseradish peroxidase-conjugated
anti-mouse and anti-rabbit goat polyclonal antibodies (Sigma-Al-
drich). After hybridization of the secondary antibodies and ex-
tensive washing, chemiluminescence detection was performed
using the Immobilon Western Chemiluminescent HRP Substrate
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for immunoblotting were anti-SOX2 (Abcam, Cambridge, UK),
anti-S100A14 (Proteintech, Chicago, IL, USA) and anti-α-tubulin
(Thermo Fisher) antibodies.
2.5. Reverse transcription-polymerase chain reaction (RT-PCR) and
quantitative RT-PCR (qRT-PCR)
The oligomers used in this study are listed in the supplemental
material (Table S1). Total RNA was puriﬁed from the cultured cells
using TRIZOL reagent (Thermo Fisher) according to the manufac-
turer's protocol. The cDNAs were subsequently prepared from the
total RNA using MMLV high-performance reverse transcriptase
(Illumina, San Diego, CA, USA) and oligo(dT) as the primer. The
condition for PCR detection was 32 cycles of ampliﬁcation of the
template by denaturing at 94 °C for one minute, primer annealing
at 55 °C for 30 s, and product extension at 72 °C for 1 min. Quan-
titative RT-PCR was performed using GoTag qPCR master mix
(Promega, Madison, WI, USA) in a StepOne real-time PCR system
(Thermo Fisher). The condition for 40 cycles of ampliﬁcation was
template denaturing at 94 °C for one minute, primer annealing at
55 °C for 30 s, and product extension at 72 °C for 45 s.
2.6. In vitro RNA pull-down assay
To identify the cellular mRNA target of SOX2, total RNA puriﬁed
from the BFTC905 cells was used in the in vitro pull-down assay.
The unbound RNAwas puriﬁed from the supernatant using TRIZOL
reagent (Thermo Fisher). Precipitated RNA was released from the
matrix by proteinase K digestion and puriﬁed using TRIZOL re-
agent, with glycogen as the precipitation carrier. Puriﬁed RNA
samples were ampliﬁed using the MessageAmp aRNA kit (Thermo
Fisher) and analyzed using a whole genome DNA microarray
(Human OneArray, Phalanx Biotech Group, HsinChu, Taiwan). The
data were submitted to Gene Expression Omnibus, NCBI, USA
(accession number GSE33207).
2.7. Massive parallel sequencing
Massive parallel sequencing was analyzed on the Illumina
platform. Total RNA was extracted from the BFTC905/shLuc and
BFTC905/shSOX2 cells. The integrity of puriﬁed RNAwas evaluated
by capillary electrophoresis in a 2100 Bioanalyzer (Agilent, Santa
Clara, CA, USA). The library was prepared with the TrueSeq
Stranded RNA Sample Prep Kit (Illumina). Sequencing was per-
formed on an Illumina Miseq sequencer and provided 10,268,595
and 11,419,579 paired-end 150-base reads for BFTC905/shLuc and
BFTC905/shSOX2, respectively. The sequences were mapped to the
human genome hg19 using TopHat 2. Annotation and estimation
of gene expression (reads per kilobase per million [RPKM]) was
performed using Cufﬂink and Cuffcompare. The data were sub-
mitted to Gene Expression Omnibus, NCBI, USA (accession number
GSE54136).
2.8. Cross-linking before immunoprecipitation (CLIP) assay and oli-
gomer-dependent RNase H digestion
The CLIP assay was performed as following. The BFTC905 cells
were washed twice with PBS and irradiated with 50 mJ/cm2 of
365 nm UV light. The cells were then lysed in radio-
immunoprecipitation assay buffer (RIPA) containing 10 mM so-
dium phosphate (pH 7.2), 150 mM sodium chloride, 2 mM EDTA,
and 1% NP-40 on ice in the presence of RNase inhibitors (Thermo
Fisher). The lysate was then subjected to DNase I (Promega) di-
gestion at 37 °C for 30 min. After removing the undissolved debris
by centrifugation at 4 °C and 14,000 g for 30 min, the supernatantwas subjected to immunoprecipitation using antibody-coated
protein A agarose beads (Sigma-Aldrich) at 4 °C for 2 h. The anti-
bodies used in CLIP assay were non-immunized control antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-SOX2 antibody
(Cell Signaling, Danvers, MA), and anti-FLAG M2 antibody (Sigma).
The beads were washed extensively three times with RIPA buffer
containing 0.1% NP-40. The RNAs associated with the matrix and in
the supernatant were then digested with proteinase K at 37 °C for
30 min, followed by puriﬁcation using TRIZOL reagent. The cDNAs
were prepared as described above, and the presence of the target
mRNAs was detected by RT-PCR. To digest the S100A14 mRNA at
speciﬁc locations, we performed oligomer-dependent RNase H
digestion on the matrix-bound mRNA after immunoprecipitation.
The CLIP procedure was followed until the precipitation step was
completed. Then, the beads were washed and incubated in the
RIPA buffer containing the targeting oligomer and 20 units of
RNase H (Illumina) at 37 °C for one hour. The RNAs in the super-
natant and on the beads were recovered and analyzed by RT-PCR.
2.9. Electrophoretic mobility shift assay (EMSA)
The T7-3′-UTR fragment constructs were prepared by annealing
the T7 forward oligomer with the antisense T7-3′-UTR oligomers,
followed by puriﬁcation through MicroSpin G-25 columns (GE
Healthcare Life Sciences). The RNA oligomers were produced by in
vitro transcription using T7 RNA polymerase (Promega) in the
presence of [P32]-α-UTP and puriﬁed by ethanol precipitation. For
each reaction, 2500 cpm of the radiolabeled RNA oligomer in 2 μl
of RIPA buffer with 1 mM MgCl2 was mixed with 2 μl of the cell
extract and incubated at room temperature for 20 min. After in-
cubation, 2 μl of loading dye was added to the reaction, and the
reaction mix was analyzed on a 4% non-denaturing poly-
acrylamide gel with 5% glycerol at 4 °C. After electrophoresis, the
gel was dried and the image was obtained by autoradiography.
2.10. Heterokaryon assay
The pSOX2-RFP plasmid was co-transfected into HeLa cells
with pEGFP-hnRNP A1 or pEGFP-hnRNP C1 for 24 h. NIH 3T3 cells
were seeded to the culture and allowed to adhere for 2 h. Co-
cultured cells were treated with 50 μg/ml cyclohexamide for 2.5 h
and then 100 μg/ml cyclohexamide for 0.5 h. The cells were fused
by treating the cultures with 50% polyethylene glycol 3350 for
90 s, followed by extensive washing with PBS and continued cul-
ture for 4 h. The cells were also ﬁxed in 4% paraformaldehyde and
counterstained with Hoechst 33250. The ﬂuorescent images were
captured using an Olympus FV1000 laser scanning microscope.3. Results
3.1. SOX2 binds to the S100A14 mRNA and regulates its cellular level
We previously identiﬁed the RNA binding activity of SOX2. The
result suggests that SOX2 potentially participates in post-tran-
scriptional regulation as an RNA binding protein. In this study, we
ﬁrst set out to identify the mRNAs directly bound by SOX2. To
screen for SOX2 binding targets, an in vitro pull down assay was
performed using control GST or GST-SOX2 fusion protein to pre-
cipitate total RNA puriﬁed from the BFTC905 cells. The RNA sam-
ples were prepared from the supernatant and matrix-bound
fractions and subsequently analyzed by expression microarray.
However, the amount of RNA precipitated by GST was nearly un-
detectable and insufﬁcient for analysis. Thus, we compared the
mRNA proﬁles from the supernatant and precipitation fractions of
the SOX2 pull down reaction to the proﬁle from the supernatant
Fig. 1. SOX2 binds to and regulates the expression of the S100A14 mRNA in BFTC905. (A) Recombinant SOX2 was used as a bait protein to precipitate puriﬁed the total RNA
from the BFTC905 cells in in vitro pull-down assays. GST served as the negative control. The RNA was puriﬁed from supernatant and precipitated fractions, followed by
microarray analysis. The genes preferentially bound by SOX2 were indicated in red. (B) BFTC905/shLuc and BFTC905/shSOX2 cells were created by infecting the BFTC905 cells
with shRNA-expressing lentiviral vectors. Suppression of SOX2 was conﬁrmed by immunoblotting. (C) Massive parallel sequencing was performed to analyze the tran-
scriptome of the BFTC905/shLuc and BFTC905/shSOX2 cells. The genes indicated in (A) was plotted against the expression change. Red color indicates more than 2-fold
change in BFTC905/shSOX2. (D) The in vitro pull-down assay was performed using GST and SOX2 as the bait proteins. The level of the S100A14 mRNA in the input,
supernatant, and precipitated fractions was determined by RT-PCR. DDIT3 serves as the non-enrichment negative control. (E) The CLIP assay was performed using either
control IgG or anti-SOX2 antibodies. The RNA was recovered from the supernatant and the matrix, and the presence of the S100A14 transcript was detected by RT-PCR. and
(F) The level of the S100A14 protein in the BFTC905/shLuc and BFTC905/shSOX2 cells was determined by immunoblotting. α-tubulin serves as the control.
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than 2-fold change between the supernatant fractions of the
control and SOX2 pull-down reactions, the SOX2-precipitated
fraction had 733 and 1011 genes with more than 2-fold decrease
and increase than the control, respectively. This drastic difference
in proﬁle indicated that SOX2 displayed binding speciﬁcity for a
subset of cellular mRNA. The precipitation efﬁciency was then
represented by the ratio between the supernatant and precipita-
tion fractions of the SOX2 pull down reaction (Fig. 1A). Among the
genes enriched in the SOX2 precipitation fraction, 124 genes
showed more than 3-fold increase and were selected for further
investigation (Fig. 1A).
Post-transcriptional regulation controls gene expression by
modulating mRNA stability and translation efﬁciency. In this study,
we focused on the genes with mRNA level post-transcriptionally
regulated by SOX2. To achieve this goal, we suppressed the ex-
pression of SOX2 in BFTC905 (Fig. 1B) and determined the change
in gene expression proﬁle by massive parallel sequencing. To avoid
false identiﬁcation of candidate genes, an FPKM of 2 was arbi-
trarily used as a threshold to select genes of sufﬁcient reads for
further analysis. In the 10,381 genes with an FPKM larger than 2,
approximately 3% of the genes showed more than 2-fold change inSOX2-depleted BFTC905. Cross-referencing the results of the in
vitro RNA pull-down assay and expression proﬁle analysis in-
dicated that S100A14, CDKN2D, and H19 were enriched in SOX2
precipitation fraction and simultaneously showed signiﬁcant
change upon depletion of SOX2 in BFTC905 (Fig. 1C). S100A14 has
been implicated in oncogenesis [27,28], but the mechanism by
which it is regulated in SOX2-positive urothelial carcinoma has not
been investigated. Hence, we focused our subsequent investiga-
tion using S100A14 as a model to illustrate the post-transcriptional
function of SOX2. Direct interaction of SOX2 with the S100A14
mRNA was validated by detecting the presence of the S100A14
mRNA in the precipitation fraction (Fig. 1D). The CLIP assay also
clearly showed that the S100A14 mRNA was preferentially en-
riched in the SOX2-precipitated fraction (Fig. 1E). Moreover, de-
pletion of SOX2 also led to a decrease in the protein level of
S100A14 (Fig. 1F), an observation also made in second SOX2-de-
pleted BFTC905 line (Fig. S2B). In TSGH8301, an urothelial carci-
noma cell line with extremely low SOX2expression, ectopic ex-
pression of SOX2 greatly increased the expression of S100A14 (Fig.
S3A). Together, our data indicated a regulation circuit that SOX2
promotes S100A14 expression by binding to and stabilizing its
transcript.
Fig. 2. SOX2 interacts with the 3′-UTR of the S100A14 mRNA in vivo. (A) The dia-
gram depicts the annealing positions of the targeting oligomer for RNase H di-
gestion and the primers for reverse transcription and PCR detection of the ORF and
3′-UTR fragments. (B) FLAG-SOX2 was transiently expressed in BFTC905 cells for
48 h, followed by the CLIP assay. The matrix-bound mRNA was incubated at 37 °C
with RNase H in the absence of the targeting oligomer for 30 min. The mock-
treated matrix-bound mRNA was then puriﬁed and reverse-transcribed. The full-
length, ORF, and 3′ fragments of the S100A14 mRNA were detected by RT-PCR.
(C) After immunoprecipitation, the matrix-bound mRNA was subject to oligomer-
dependent RNase H digestion at 37 °C for 30 min. The ORF and 3′-UTR fragments of
the S100A14 mRNA in the supernatant and bound to the matrix were recovered,
reverse transcribed, and detected by semi-quantitative PCR.
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S100A14 mRNA
Post-transcriptional regulation depends on the recognition of
the 3′-UTR sequences by trans-acting regulatory factors [29,30]. It
is likely that SOX2 regulates S100A14 through a similar mechan-
ism. To determine whether SOX2 binds to the S100A14 3′-UTR, we
coupled the CLIP assay with oligomer-dependent RNase H diges-
tion. The target sequence of the antisense oligomer is located at
the 5′-end of the S100A14 3′-UTR. Cleavage of the S100A14 mRNA
by RNase H produces the ORF and 3′-UTR fragments, and the ORF
and 3′-UTR fragments was detected by RT-PCR (Fig. 2A). Tran-
siently expressed FLAG-SOX2 was immunoprecipitated from
BFTC905, and RNase H digestion was performed in the absence
(Fig. 2 B) or presence (Fig. 2C) of the targeting antisense oligomer.
In the absence of the targeting oligomer, detection of the full-
length product indicated that the RNase H treatment alone does
not compromise the integrity of the S100A14 mRNA on the matrix
(Fig. 2B). In contrast, most of the ORF fragment was released from
the matrix to the supernatant after digestion in the presence of theantisense oligomer, while the majority of the 3′-UTR fragment was
still bound to the matrix (Fig. 2C). Hence, the result clearly showed
that SOX2 preferentially binds to the 3′-UTR of S100A14.
The length of the S100A14 3′-UTR is approximately 650 nu-
cleotides. To locate the SOX2 binding site in the 3′-UTR, we dis-
sected the 3′-UTR into 6 fragments and cloned the 3′-UTR frag-
ments to the pEGFP-C2 vector. An in-frame stop codon was placed
between the EGFP ORF and the cloned fragments, making the
cloned fragments functioning as the 3′-UTR of the EGFP reporter
mRNA. The structures of the S100A14 3′-UTR reporters are de-
picted in Fig. 3A. The reporters were expressed with FLAG-tagged
SOX2 in BFTC905, and the interaction between SOX2 and the 3′-
UTR reporter mRNA was examined by the CLIP assay. The result
showed that the S100A14 643-784 sequence was precipitated by
SOX2 with approximately 25-fold higher efﬁciency than that of the
control EGFP mRNA (Fig. 3B and C), indicating that this region
contains the SOX2 binding site.
We next dissected the 3′-UTR sequence between nucleotide
643 and 784 into six 32-nucleotide-long fragments with a 10
nucleotide overlap between them (Fig. 3D). These sequences were
then used to generate radiolabeled RNA oligomers in vitro. These
probes were incubated with the extracts prepared from BFTC905
with transiently expressed SOX2 or control β-galactosidase, and
the protein-RNA mix was analyzed by non-denaturing acrylamide
gel electrophoresis. Among these probes, the probes 687-718 and
709-740 showed retarded mobility. Furthermore, ectopic expres-
sion of SOX2 increases the retardation of probe 684-710, but not
probe 710-740 (Fig. 3E), indicating that the sequence element for
SOX2 binding resides in the sequence between nucleotide 684 and
710. A structural analysis of the sequence revealed that this se-
quence forms an stem-loop structure (Fig. 3F). Thus, our data de-
monstrated that SOX2 binds to a stem-loop structure in the 3′-UTR
of the S100A14 mRNA.
3.3. SOX2 shuttles between the nucleus and cytoplasm
Many trans-acting RNA binding proteins are predominantly
localized in the nucleus where initial binding to the target mRNA
occurs. The protein-mRNA complexes are exported to the cyto-
plasm for execution of the regulatory pathway, and these RNA
binding proteins then shuttle back to the nucleus after releasing
from the complex [31]. Lacking a nuclear export signal, SOX2 can
not be exported back to the cytoplasm in a CRM1-dependent
pathway. Thus, the shuttling activity of SOX2 would be due to
through the formation and export of the mRNA-protein complex.
To demonstrate the shuttling activity of SOX2, we performed the
heterokaryon assay to examine whether SOX2 will return to the
cytoplasm from the nucleus. For this assay, SOX2-RFP was co-ex-
pressed with either EGFP-hnRNP A1 or EGFP-hnRNP C1 in HeLa
cells, followed by fusion with NIH3T3 cells. As shown in Fig. 4, the
result of the heterokaryon assay indicates that SOX2-RFP exhibited
similar intracellular movement as EGFP-hnRNP A1 (Fig. 4, panels
A–F). Meanwhile, EGFP-hnRNP C1 remained restricted to the nu-
clei (Fig. 4, panels G–L). Although the shuttling movement of
SOX2-RFP appears to be slower than hnRNP A1-EGFP, our data still
added support to the notion that SOX2 binds to the target mRNA in
the nucleus and is subsequently transported to the cytoplasm as a
component of the mRNP.
3.4. Suppression of SOX2 promotes the growth and mobility of
BFTC905 cells
We next examined the cellular function of SOX2 in BFTC905.
Compared to the control BFTC905/shLuc, BFTC905/shSOX2 dis-
played a slightly faster growth rate (Fig. 5A). Cell cycle analysis
showed that the percentage of BFTC905/shSOX2 cells in S and G1
Fig. 3. The SOX2 binding site displays extensive secondary structure. (A) The diagram depicts the structures of the EGFP-S100A14 3′-UTR fragment reporters. Each 3′-UTR
fragment was cloned into pEGFP-C2 with an in-frame translation stop codon located at the 5′-end of the fragment. (B) The EGFP-S100A14 3′-UTR reporters were co-
expressed with FLAG-SOX2 in BFTC905 cells for 72 h. The CLIP assay was performed using the control IgG and anti-SOX2 antibodies. The EGFP-3′-UTR fragment mRNAs in the
input, supernatant, and bound to the matrix were detected by RT-PCR to amplify the EGFP coding sequence. DITT3 serves as negative control. (C) The band intensities in
(B) were quantiﬁed using ImageJ. The enrichment of the S100A14 3′-UTR reporters were calculated by following formula: [FLAG elute/(FLAG supþFLAG sup)]/[IgG elute/(IgG
supþ IgG elute)]. (D) The diagram depicts the sequences of the oligomers used to produce the 32-mer EGFP-S100A14 3′-UTR RNA fragments. (E) The in vitro synthesized RNA
was incubated with β-galactosidase or SOX2-expressing BFTC905 cell extracts and analyzed by non-denaturing polyacrylamide electrophoresis. (F) The primary sequence
between nt 687 and 740 was listed. The RNA oligomer for nt 687-718 is the sequence in gray box. The secondary structure of the S100A14 sequence between nt 687 and 740
predicted by Mfold is shown.
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Together, the result suggests that suppression of SOX2 endows
BFTC905 a slight growth advantage. Our unpublished data showed
that the percentage of the SOX2-positive cells is often limited in
the clinical specimens, indicating a mixed tumor cell population in
the tumor mass (data not shown). Thus, we further tagged the
control BFTC905/shLuc and SOX2-depleted BFTC905/shSOX2 cell
lines with the TagRFP and EGFP ﬂuorescence proteins. These two
cell lines, BFTC905/shLuc-TagRFP and BFTC905/shSOX2-EGFP, were
then mixed together and co-cultured for 15 days to simulate the
coexistent environment in the tumor mass. At days 0 and 15, the
percentage of BFTC905/shSOX2-EGFP cells in the population was
determined by randomly imaging the cell population using a
confocal laser scanning microscope (Fig. 5B). At the end of the 15-
day period, the percentage of BFTC905/shSOX2-EGFP cells in the
population was approximately more than 50% even though the
initial percentage was relatively low (Fig. 5C), We also examined
the growth of an additional BFTC905/shSOX2 cell line and found
that it also displayed an increase in growth (Fig. S2C), further
supporting our ﬁnding. Together, our data indicate that expression
of SOX2 slows the growth of BFTC905.In addition to the growth rate, we examined whether depletion
of SOX2 alters the mobility of BFTC905. In the wound healing as-
say, the BFTC905/shSOX2 cells narrowed the gap more rapidly
than the control BFTC905/shLuc cells (Fig. 5D), a ﬁnding collabo-
rated by second SOX2-depleted BFTC905 (Fig. S2D). In contrast,
expression of SOX2 decreased the mobility of S100A14 (Fig. S3B).
We also examined the effect of SOX2 suppression by seeding
mixed BFTC905/shLuc-TagRFP and BFTC905/shSOX2-EGFP cells in
the upper chamber of the transwell apparatus. Twenty-four hours
after removing the serum from the upper chamber, those cells that
had migrated to the lower chamber were identiﬁed by ﬂuores-
cence imaging. The result showed that there were signiﬁcantly
more BFTC905/shSOX2-EGFP cells migrating to the lower chamber,
demonstrating an increase of mobility upon depletion of SOX2
(Fig. 5E). Thus, our data suggests that SOX2 likely act as a tumor
suppressor in BFTC905.
3.5. Suppression of S100A14 leads to an increase in the growth and
mobility of BFTC905 cells
Our data has established that SOX2 binds to the 3′-UTR of the
S100A14 mRNA and that depletion of SOX2 resulted in a decrease
Fig. 4. SOX2 shuttles between the nucleus and the cytoplasm. EGFP-hnRNP A1 or EGFP-hnRNP C1 was transiently co-expressed with SOX2-RFP in HeLa cells for 48 h. NIH3T3
cells were then seeded with the transfected HeLa cells for two hours, followed by cyclohexamide treatment. The culture was then treated with PEG to induce cell fusion. After
PEG-induced cell fusion, the culture was incubated for additional 4 h and ﬁxed. The nuclei were stained with Hoechst 33258. The images were acquired using an Olympus
laser scanning confocal microscope.
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sociated with poor prognosis in colorectal cancer and oral squa-
mous cell carcinoma [28,32]. Moreover, restoring of S100A14 ex-
pression in oral squamous cell carcinoma cell lines signiﬁcantly
decreases their invasive potential and cell growth [33], suggesting
that S100A14 can function as an oncosuppressor. To examine
whether S100A14 plays a similar role in urothelial carcinoma, we
suppressed S100A14 expression in BFTC905 by expression of an
anti-S100A14 shRNA (Fig. 6A). The cell cycle analysis of theBFTC895/shS100A14 cells showed that there was a clear decrease
in the number of cells in G1 phase and a simultaneous increase in
the number of the cells in S phase (Fig. 6B), indicating a shorter G1
phase. In addition to an increase of cell cycle progression, the
BFTC905/shS100A14 cells also exhibited increased mobility in the
wound healing assay (Fig. 6C). Taken our data together, our ex-
perimental results indicated that SOX2 suppresses cell growth and
mobility by promoting the expression of S100A14 through post-
transcriptional regulation.
Fig. 5. Suppression of SOX2 leads to an increase in the growth and mobility of BFTC905 cells. (A) The day after seeding the BFTC905/shLuc and BFTC905/shSOX2 cells was
designated as day 0. The cell density of an initial 1106 cells was determined by crystal violet staining. The cultures with 5105, 2.5105, or 1.25105 cells were allowed
to grow for additional one, two, and three days, respectively. At each time point, the cell densities were determined by crystal violet staining, and the readings were
normalized by multiplying the value with the number of respective days. The relative increase in the cell density was calculated by dividing the normalized crystal violet
reading with the reading of the day 0 culture. Student's t-test was carried out to determine the statistical signiﬁcance of the differential growth at each point. The p value
smaller than 0.05 is represented as an asterisk. (B) The BFTC905/shLuc-RFP and BFTC905/shSOX2-EGFP cells were created by transfecting the BFTC905/shLuc and BFTC905/
shSOX2 cells with pTag-RFP-N and pEGFP-C1, respectively. After two weeks of antibiotic selection, the cells expressing the ﬂuorescent proteins were collected using a BD
FACS Aria III cell sorter. The BFTC905/shLuc-RFP and BFTC905/shSOX2-EGFP cells were then mixed together and cultured in a glass-bottom dish under normal growth and
passage conditions for 15 days. At days 0 and 15, the cells were imaged using an Olympus laser scanning confocal microscope. (C) The percentage of BFTC905/shSOX2-EGFP
cells in the population was determined by counting more than 200 cells from 10 random images. The results of three independent experiments are shown. (D) The BFTC905/
shLuc and BFTC905/shSOX2 cells were seeded in the cell inserts for 24 h. After the inserts were removed, the cells were cultured in medium containing 1% fetal bovine serum
for 24 h. The images were captured with a differential interference contrast-equipped microscope at 0 and 24 h. (E) Equal numbers of BFTC905/shLuc-RFP and BFTC905/
shSOX2-EGFP cells were seeded into the upper chamber of the transwell apparatus. After attachment, the cells were allowed to migrate in the absence of serum for 24 h. The
total cells were ﬁrst imaged using a ﬂuorescence microscope (panels A–C). After removing the non-migrating cells on the upper side of the transwell membrane, the
remaining cells on the lower side were imaged using an Olympus laser scanning confocal microscope (panels D– F).
Fig. 6. S100A14 depletion promotes the entry into S phase and accelerates the movement of BFTC905 cells. (A) A lentiviral vector expressing the anti-S100A14 shRNA was
delivered into BFTC905 cells to establish the BFTC905/shS100A14 cells. The suppression of S100A14 expression in the BFTC905/shS100A14 cells was determined by im-
munoblotting. (B) The percentages of BFTC905/shLuc and BFTC905/shS100A14 cells in G1, S, and G2/M phases of the cell cycle was determined by ﬂow cytometry analysis.
The statistical difference was determined using the Student's t-test. (C) BFTC905/shLuc and BFTC905/shS100A14 cells were seeded in the cell inserts for 24 h. After the inserts
were removed, the cells were cultured in medium containing 1% fetal bovine serum for 24 h. The images were captured with a differential interference contrast-equipped
microscope at 0, 10, and 24 h.
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In this study, we show that SOX2 binds to the 3′-UTR of the
S100A14 mRNA and promotes its expression. Although SOX2 is
undoubtedly a transcription factor, our experimental evidence
indicates that, in addition to DNA binding, SOX2 also functions as
an RNA binding protein. It has been demonstrated that the
members of the HMG protein family, including SRY, SOX6, and
SOX9, play a role in splicing, thus suggesting that these HMG do-
main proteins bind to RNA. Our study adds SOX2 to the list of RNA-
binding HMG proteins and implies that other HMG proteins
function in post-transcriptional regulation as well. It was reported
that p53 participates in microRNA biogenesis and that WT1
functions in splicing. Together, these ﬁndings raise the possibility
that a subset of transcription factors also bind to RNA and parti-
cipate in post-transcriptional regulation. Post-transcriptional reg-
ulation includes alternative splicing, the modulation of mRNA
stability, and the control of translation efﬁciency [31]. Due to the
methodology employed in this study, only those genes with their
mRNA stability regulated by SOX2 were identiﬁed, and we did not
rule out that SOX2 may also participate in other post-transcrip-
tional regulation mechanisms.
Previous studies have determined the consensus DNA binding
sequence of SOX2 as ACAAAG [34]. However, characterization of
the SOX2-occupied chromosome sites in embryonic stem cells,
neuronal progenitor cells, and cancer cell lines indicated that SOX2
is targeted to distinct genomic locations in different types of cells
[24,35–39]. This is because the targeting speciﬁcity of SOX2 is not
only determined by its binding preference, but is also dictated by
its cofactors. Our result indicates that SOX2 is capable of binding to
speciﬁc RNA sequences, and the most prominent feature of the
SOX2 binding sequence on the S100A14 3′-UTR is a stem-loop
structure. This ﬁnding suggests that SOX2 acts as a double-stran-
ded RNA binding protein. On the other hand, sequence analysis
prediction indicated that multiple RNA protein binding sequences
are located in the immediate downstream sequence of the stem-
loop structure. Some of these putative RNA binding proteins, in-
cluding hnRNP A1, hnRNP F, LIN28A, SRSF1, and TRA2A, are highly
expressed in BFTC905 cells. A potential seed sequence for hsa-miR-
4267 was also predicted in this region. Although which RNA pro-
tein binds to this region remained to be determined, it is likely
that SOX2 interacts with additional RNA binding protein in the
nearby vicinity to form a functional protein complex. How this
SOX2-containing RNA binding complex increases the level of the
S100A14 mRNA requires further investigation, but the investiga-
tion will illustrate the molecular mechanisms of how SOX2 func-
tions in post-transcriptional regulation.
It has been shown that stem cell markers, such as SOX2, are
activated more frequently in poorly differentiated tumors and are
generally correlated with a poor prognosis [40], suggesting that a
reversal to a stem cell property facilitates the growth and inva-
siveness of tumours. Consistent with this view, the induced ex-
pression of SOX2 in the lungs of adult mice was sufﬁcient to drive
the development of adenocarcinoma [41]. However, SOX2 ex-
pression is required to maintain normal gastric epithelial stem
cells, and the loss of SOX2 leads to a complete conversion from
gastric to intestinal epithelial characteristics. [42,43]. Epigenetic
silencing of SOX2 was frequently observed in intestinal-type gas-
tric cancer, and poor prognosis was associated with the down-
regulation of SOX2 [42,44]. Hence, the role of SOX2 in oncogenesis
apparently depends on the nature of the cell origin. Expression of
SOX2 have been conﬁrmed in urothelial carcinoma, and expression
of SOX2 in non-muscle-invasive bladder cancer was correlated
with tumor size and poorer survival [45]. Given the heterogeneous
nature of cancer, SOX2 expression likely represents a signature of
one oncogenic pathway. The observation is consisted with theview that cancer with stem cell property is more aggressive and
results in poor outcome. However, a more recent study showed
that microRNA-145 increases the expression of the stem cell
markers, including SOX2, and induces differentiation of urothelial
carcinoma cell line [46]. Thus, whether SOX2 expression is ne-
cessarily the signature of the stem cell property in urothelial car-
cinoma remained to be clariﬁed. It is possible that the cellular
function activated by SOX2 in urothelial carcinoma also depends
on the context of the cofactor proﬁle.
Among the urothelial carcinoma cell lines we have examined,
BFTC905 is the only cell line in which SOX2 was readily detected
by both immunoblotting and immunostaining. Morphologically,
BFTC905 displays an epithelial morphology and tends to adhere to
neighboring cells to form large cell islets. On the other hand,
TSGH8301, an urothelial carcinoma cell line from a poor-differ-
entiated stage-II patient, displays weaker attachment to the cul-
ture surface nor adheres to the neighboring cells. Since SOX2
promotes the differentiation of the urothelial epithelium [46],
SOX2 likely plays a similar function as in gastric epithelium, which
is to maintain the normal function of the epithelium. Conse-
quently, loss of SOX2 leads to dysregulation of epithelial cells. In
addition to the urothelial carcinoma, loss of SOX2 may also play a
role in oncogenesis of other epithelial tissues in which SOX2 is
required for normal function and maintenance. Additional studies
on other types of carcinoma are needed to collaborate with this
compelling hypothesis.Acknowledgments
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